Education
About Us
Working with TipRanks
Follow Us
Vaccinex (VCNX)
:VCNX
VCNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $8.90
Previous CloseN/A
Volume245.00
Average Volume (3M)4.39K
Market Cap
$1.90M
Enterprise Value$5.57M
Total Cash (Recent Filing)-$1.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.58
Shares Outstanding2,599,728
10 Day Avg. Volume2,825
30 Day Avg. Volume4,389
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.82
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.77
Enterprise Value/Ebitda-0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ownership Overview
52.86% Insiders
0.15% Mutual Funds
6.31% Other Institutional Investors
40.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VCNX FAQ
What was Vaccinex’s price range in the past 12 months?
Vaccinex lowest stock price was $0.25 and its highest was $8.90 in the past 12 months.
What is Vaccinex’s market cap?
Vaccinex’s market cap is $1.90M.
When is Vaccinex’s upcoming earnings report date?
Vaccinex’s upcoming earnings report date is May 19, 2025 which is in 37 days.
How were Vaccinex’s earnings last quarter?
Currently, no data Available
Is Vaccinex overvalued?
According to Wall Street analysts Vaccinex’s price is currently Overvalued.
Does Vaccinex pay dividends?
Vaccinex does not currently pay dividends.
What is Vaccinex’s EPS estimate?
Vaccinex’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex have?
Vaccinex has 2,599,728 shares outstanding.
What happened to Vaccinex’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaccinex?
Currently, no hedge funds are holding shares in VCNX
---
Company Description
Vaccinex
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
---
VCNX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---